ISO is developing an electronic skin-screening device that will help medical staff in the community to monitor patients’ skin and moles as a Decision Supporting Tool. Worldwide, more skin cancers are diagnosed each year than all other cancers combined and this number is constantly increasing. However, skin screening is usually performed by dermatologists and the majority of the population don’t have the accessibility and/or the means to see a dermatologist. They have access to community clinics, pharmacies, and points of care but they don’t perform skin screening because they don’t have the expertise nor reliable device as a Decision Supporting Tool to identify early signs of skin cancer. Therefore, our target audience is family and general physicians and nurses within community clinics and points of care.
The device contains four independent technologies in different wavelengths, that detect different signs of skin cancer. The images and data will be analyzed with customized ...
ISO is developing an electronic skin-screening device that will help medical staff in the community to monitor patients’ skin and moles as a Decision Supporting Tool. Worldwide, more skin cancers are diagnosed each year than all other cancers combined and this number is constantly increasing. However, skin screening is usually performed by dermatologists and the majority of the population don’t have the accessibility and/or the means to see a dermatologist. They have access to community clinics, pharmacies, and points of care but they don’t perform skin screening because they don’t have the expertise nor reliable device as a Decision Supporting Tool to identify early signs of skin cancer. Therefore, our target audience is family and general physicians and nurses within community clinics and points of care.
The device contains four independent technologies in different wavelengths, that detect different signs of skin cancer. The images and data will be analyzed with customized image analysis and artificial intelligence algorithms. The algorithm will be able to learn and improve its ability to recognize these signs and use external open data bases of skin cancer.
More information

Employees

Galit Ankri-Eliahoo
Admin
Galit Ankri-Eliahoo CEO I have a Ph.D. in Biomedical engineering after a post-doctoral and lab manager position in UW. With extensive experience in R&D and managing